New price of $2,753 for the GraftAssureCore™ assay increases total addressable market size and margin opportunity Brings pricing in line with existing competitive technology Expands market appeal for prospective FDA-cleared kitted product at transplant centers IRVINE, Calif., May 19, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp., (Nasdaq: OCX), a diagnostics technology company,… Read More..

MIAMI, May 16, 2025 (GLOBE NEWSWIRE) -- NextNRG, Inc. (Nasdaq: NXXT), a pioneer in AI-driven energy innovation—transforming how energy is produced, managed and delivered through its advanced Utility Operating System, smart microgrid technology, wireless EV charging and on-demand mobile fuel delivery solutions— today announced preliminary unaudited financial results for April 2025.… Read More..

Statistically significant safety and efficacy data from 0.25 mg and 0.50 mg cohorts to be presented Presentation scheduled for Thursday, May 15, 2025, at 11:36 a.m. PT PITTSBURGH, May 15, 2025 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella,” “we,” “our,” or the “Company”), a clinical-stage biotechnology company focused… Read More..